Altered Bacterial Bile Acid Metabolism as a Driver of CVID Enteropathy
细菌胆汁酸代谢的改变是 CVID 肠病的驱动因素
基本信息
- 批准号:10227914
- 负责人:
- 金额:$ 20.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAntibodiesAutomobile DrivingBile AcidsBody Weight decreasedChronicChronic diarrheaCommon Variable ImmunodeficiencyComplicationDataDiagnosisDietary FatsHealthHumanHydrolaseIgA DeficiencyImmunoglobulin AImmunoglobulin GImmunoglobulin MIn VitroInflammationLaboratory miceMalabsorption SyndromesMetabolic DiseasesMetabolismModelingMucous MembraneMusPathologicPatientsPhasePhenotypePlayRegulationRoleShapesTestingabsorptionbile acid metabolismbile saltscommensal bacteriacongenital immunodeficiencydietary manipulationdietary supplementsdysbiosisexperimental studygastrointestinal symptomhypogammaglobulinemiain vivo Modelmicrobial communitymicrobiomemicrobiotamouse modelmutant
项目摘要
Antibody deficiency is the most frequently diagnosed form of primary immunodeficiency in humans. Common variable immunodeficiency (CVID) is the most severe form of antibody deficiency and is characterized as hypogammaglobulinemia (low IgG) with an accompanying deficit in IgA and/or IgM titers. In both humans and laboratory mouse models, IgA deficiency has been associated with alterations to the composition and function of symbiotic microbial communities (a.k.a. the microbiota) in the gut, and emerging data from CVID patients indicate that a similar association exists. Up to 50% of CVID patients will develop gastrointestinal symptoms, and the major complication of CVID is CVID enteropathy. CVID enteropathy most often presents as chronic diarrhea and weight loss due to an underlying intestinal malabsorption. The pathophysiological mechanism driving CVID enteropathy is not known but pathological alterations to the microbiota ('dysbiosis') could be a key factor. Bile acids (BAs) are secreted into the gut where they play a crucial role in the emulsification of dietary lipids that facilitates their absorption. The microbiome plays a central role in shaping BA composition in the gut. Thus, dysbiosis caused by gut antibody deficiency may drive CVID enteropathy and associated metabolic disease by influencing BA metabolism in the gut. The objective of Specific Aim #1 is to test that intestinal malabsorption is an IgA-dependent phenotype using adoptive transfer models in antibody deficient recipients. The objective of Specific Aim #2 is to specifically test that bacterial bile salt hydrolase (bsh) activity results in enhanced BA deconjugation that drives malabsorption in antibody deficient mice. Mono-colonization experiments in germfree Ig-deficient mice using WT and bsh-null mutant strain of commensal bacteria will be used to address this hypothesis. The objective of Specific Aim #3 is to determine the impact of altered BA pools on host metabolism using a mixture of in vitro and in vivo models. Collectively, these experiments are the first to address the role of mucosal IgA deficiency in the context of CVID on the regulation of bacterial BA metabolism and its effect on host health. Several approaches will be utilized to assess the feasibility of treating malabsorption and chronic inflammation through dietary manipulation of the microbiome.
抗体缺乏症是人类原发性免疫缺陷最常见的诊断形式。常见变异型免疫缺陷(CVID)是最严重的抗体缺乏形式,其特征为低丙种球蛋白血症(低IgG),伴有伊加和/或IgM滴度缺陷。在人类和实验室小鼠模型中,伊加缺乏症均与共生微生物群落的组成和功能改变有关(又名肠道中的微生物),来自CVID患者的新数据表明存在类似的关联。高达50%的CVID患者会出现胃肠道症状,CVID的主要并发症是CVID肠病。CVID肠道病最常见的表现是由于潜在的肠道吸收不良而导致的慢性腹泻和体重减轻。驱动CVID肠病的病理生理学机制尚不清楚,但微生物群的病理学改变(“生态失调”)可能是一个关键因素。胆汁酸(BA)被分泌到肠道中,在乳化促进吸收的膳食脂质中起着至关重要的作用。微生物组在形成肠道中的BA组成中起着核心作用。因此,由肠道抗体缺乏引起的生态失调可能通过影响肠道中的BA代谢来驱动CVID肠病和相关代谢疾病。具体目标#1的目的是在抗体缺陷受体中使用过继转移模型检测肠道吸收不良是否为IgA依赖性表型。具体目标#2的目的是专门测试细菌胆盐水解酶(bsh)活性导致BA去缀合增强,从而导致抗体缺陷小鼠吸收不良。将使用无菌Ig缺陷小鼠中的WT和bsh无效突变体菌株的大肠杆菌单菌落实验来解决这一假设。具体目标#3的目的是使用体外和体内模型的混合物确定改变的BA合并液对宿主代谢的影响。总的来说,这些实验是第一个解决粘膜伊加缺乏症在CVID背景下对细菌BA代谢调节的作用及其对宿主健康的影响。将利用几种方法来评估通过饮食操纵微生物组治疗吸收不良和慢性炎症的可行性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason L Kubinak其他文献
Jason L Kubinak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason L Kubinak', 18)}}的其他基金
Humoral immunodeficiency disrupts bile-acid-induced immune tolerance in the small intestine
体液免疫缺陷破坏胆汁酸诱导的小肠免疫耐受
- 批准号:
10664252 - 财政年份:2022
- 资助金额:
$ 20.31万 - 项目类别:
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10409841 - 财政年份:2021
- 资助金额:
$ 20.31万 - 项目类别:
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10299067 - 财政年份:2021
- 资助金额:
$ 20.31万 - 项目类别:
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10614060 - 财政年份:2021
- 资助金额:
$ 20.31万 - 项目类别:
Altered Bacterial Bile Acid Metabolism as a Driver of CVID Enteropathy
细菌胆汁酸代谢的改变是 CVID 肠病的驱动因素
- 批准号:
10220550 - 财政年份:2020
- 资助金额:
$ 20.31万 - 项目类别:
Exploring how B cell Maturation Pathways Influence Microbiota Composition and Host Health
探索 B 细胞成熟途径如何影响微生物群组成和宿主健康
- 批准号:
9089576 - 财政年份:2017
- 资助金额:
$ 20.31万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 20.31万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 20.31万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 20.31万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 20.31万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 20.31万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 20.31万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 20.31万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 20.31万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 20.31万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 20.31万 - 项目类别: